- Case report
- Open Access
Pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma of the lower limb: report of a rare case
© Fan et al. 2015
- Received: 26 April 2015
- Accepted: 14 August 2015
- Published: 28 August 2015
Pseudomyogenic hemangioendothelioma is an extremely rare soft tissue tumor, also named as epithelioid sarcoma-like hemangioendothelioma, which occurs more frequently in young adult males. It was originally recognized as a variant of epitheloid sarcoma, however it is now concluded as a distinctive, rarely metastasizing endothelial neoplasm. We present a case of pseudomyogenic hemangioendothelioma in the lower limb in a 49-year-old female who has a long course of disease and suffered from twice local recurrences and lymph node affection of the tumor. The mass was subcutaneous and the margins were ill-defined. Morphologically, the tumor cells show diversity, composed of large spindle cells and round cells, both with abundant eocinophilic cytoplasm, mimicking rhybdomyoplasts and epitheloid cells respectively. The tumor cells show diffuse strong expression of Factor VIII, Fli-1, INI-1, vimentin, MDM2, and CDK4, local expression of CD31, AE1/AE3, EMA and P63, and no expression of CD34, S-100, actin-sm, desmin, MyoD1, and HMB45. Based on these information, this case is diagnosed as pseudomyogenic hemangioendothelioma after ruling out the main differential diagnosises including epithelioid sarcoma, malignant peripheral nerve sheath tumor and rhabdomyosarcoma. From this case we suggest that pseudomyogenic hemangioendothelioma may be confused with a variety of soft tissue neoplasm histologically. The clinical feature of the case of a long course of disease with twice local recurrences and final lymph node involvement 10 years after excision of the primary tumor indicates a relative indolent behavior of this tumor.
- Factor VIII
- Malignant Peripheral Nerve Sheath Tumor
- Young Adult Male
- Epithelioid Sarcoma
Pseudomyogenic hemangioendothelioma, also known as epithelioid sarcoma-like hemangioendothelioma, occurs more frequently in young adult males and usually arises in the extremities, especially on the lower limb, and often involves multiple tissue planes [1–5]. It histologically mimics a myoid tumor or epithelioid carcinoma due to abundant eosinophilic cytoplasm and the cell shape [1–5]. It is now characterized as a distinctive, rarely metastasizing endothelial neoplasm . The tumor is composed of large round or spindle cells, or commonly both parts, arranged in sheets or fascicles. The cells rarely show notable pleomorphism or nuclear atypia [1–3]. Clinically, more than half of the patients experience local recurrence, and lymph node and distant metastasis in a few cases has also been reported [1–9]. In the case we present here, the patient experienced a long course of disease and twice recurrences and lymph node involvement of the tumor after excision of the primary tumor 10 years ago. Morphologically, the tumor is composed of both areas of round and spindle cells with abundant eocinophilic cytoplasm, which may lead to confusion with a variety of other soft tissue neoplasm such as epithelioid sarcoma, malignant peripheral nerve sheath tumor and rhabdomyosarcoma. The immunophenotype of expression of INI-1, AE1/AE3, and endothelial markers such as Factor VIII, Fli-1 and CD31, and negative staining of desmin, MyoD1, and S-100 supports the diagnosis of pseudomyogenic hemangioendothelioma in this case.
A 49-year-old female referred to our hospital for recurrence of soft tissue tumor with multiple nodules in her left lower limb. MRI shows that the nodules were subcutaneous at the left calf below the knee and integrated to a mass about 6 cm × 5 cm. The mass has been growing up gradually for 2 years without treatment. Before that, the patient had a primary tumor about 1 cm × 1 cm in the same location about 10 years ago. The patient experienced once recurrence with a new mass at the same location around the incision 2 years after local excision of the primary one. This new mass grew up to about 5 cm × 3 cm in 3 years and then the patient received a second surgery. And now it is the second recurrence of the tumor and the third time for her to receive surgery. MRI also detected a subcutaneous mass about 3.2 cm × 3.4 cm at her left thigh near the inguinal area this time. Blood test of the patient shows no abnomity. The urinary test shows slight high levels of red blood cells (5.11/HPF), white blood cells (3.09/HPF), epithelial cells (2.02/HPF) and urea (7.73 mmol/L).
Materials and methods
The resected specimens of the tumor were fixed with 10 % neutralbuffered formalin and embedded in paraffin blocks. Tissue blocks were cut into 4 μm-thick sections and the sections were dewaxed in xylene and rehydrated stepwise in descending ethanol series. Then the sections were boiled in citrate buffer (pH 6.0) within an autoclave. Endogenous peroxidase activity and non-specific binding were blocked with 3 % H2O2 and non-immune sera, respectively. The sections were then incubated with the following primary antibodies: actin-sm (1:50, DAKO), AE1/AE3 (1:50, DAKO), CD31 (1:100, DAKO), CD34 (1:100, DAKO), cytokeratin 18 (CK18, 1:200, DAKO), cytokeratin 19 (CK19, 1:200, DAKO), CDK4 (1:50, Abcam), desmin (1:50, DAKO), EMA (1:100, DAKO), Fli-1 (1:100, Abcam), Factor VIII (1:100, Abcam), HMB45 (1:50, Abcam), INI-1 (1:100, Santa Cruz), Ki67 (1:200, DAKO), Melan-A (1:50, DAKO), myoD1 (1:50, DAKO), MDM2 (1:50, Abcam), P63 (1:100, DAKO), S-100 (1:50, DAKO), and vimentin (1:200, DAKO) overnight at 4 °C. Thereafter, the catalyzed signal amplification system (Maixin Biotechnology, Fuzhou, Fujian, China) was used for staining of these proteins according to the manufacturer’s instructions. The antibodies were detected by a standard avidin-biotin complex method with biotinylated secondary antibodies (Maixin) and an avidin-biotin complex (Maixin), and developed with diaminobenzidine. Counterstaining was done lightly with hematoxylin, and the sections were dehydrated in alcohol before mounting. This study was prospectively performed and approved by the institutional Ethics Committees of China Medical University and conducted in accordance with the ethical guidelines of the Declaration of Helsinki.
Pseudomyogenic hemangioendothelioma, also named as epithelioid sarcoma-like hemangioendothelioma, which morphologically mimics a myoid tumor or epithelioid carcinoma, is now concluded as a distinctive, rarely metastasizing endothelial neoplasm [1–5]. This tumor occurs more frequently in young adult males and usually arises in the extremities [1–5]. In the case we presented here, the patient was a 49-year-old female who had a long course of disease about 10 years with this tumor in her lower limb.
The tumor is composed of large spindle cells, arranged in sheets or fascicles. Tumor cells with epithelioid cytomorphology are also often present [1–5]. In this case, the tumor is subcutaneous and both areas with spindle cells and round epithelioid cells exist. The cells are large and have abundant eosinophilic cytoplasm, mimicking a myoid tumor or epithelioid carcinoma cells. The tumor cells are plump, but show no apparent pleomorphism. The nuclei of the cells have small nucleoli without notable atypia and the mitotic activity is scarce. Based on these information, the main differential diagnosises should include epithelioid sarcoma, malignant peripheral nerve sheath tumor and rhabdomyosarcoma. Epithelioid sarcoma is a mesenchymal neoplasm exhibiting epithelioid cytomorphology, the classic subtype of which often occurs in the extremity . Spindle tumor cells can also present in this tumor. The cell pleomorphism and nuclear atypia are not notable usually in this tumor either. However classic epithelioid sarcoma usually consists of cellular node with central degeneration which is not seen in this case though it cannot be ruled out only based on this feature. The tumor cells in this case exhibit abundant eosinophilic cytoplasm mimicking myoid tumor. Thus rhabdomyosarcoma or leiomyosarcoma should also be considered. Leiomyosarcoma is a malignant neoplasm exhibiting pure smooth-muscle differentiation . The tumor consists mainly of spindle sells arranged in fascicles. However epithelioid cytomorphology can also exist, though relatively rare. The nuclear pleomorphism is generally notable in leiomyosarcoma which was not seen in this case. There are several subtypes of rhabdomyosarcoma, among which spindle cell/sclerosing rhabdomyosarcoma is the most important to be differentiated for this case. This subtype has spindle cell morphology with eosinophilic cytoplasm and shows a fascicular or plaxiform growth pattern . Epithelioid cells are rare and nuclear atypia is common in this subtype, which is different from this case. Malignant peripheral nerve sheath tumor is a malignant tumor arising from peripheral nerves, which mostly arises in the extremities . Typical type of this tumor consists of spindle cells showing a fascicular growth pattern. However there is also an epithelioid subtype of this tumor composed of epithelioid cells with abundant eosinophilic cytoplasm, which should also be considered for this case. The neoplasmic cells of this type are cohesive together or scattered and embedded in the extracellular myxoid matrix. The similar areas also exist in this case. However prominent nucleoli are often seen in the tumor cells of this type but not in this case. Moreover areas with spindle cells are also main parts of the tumor in this case which is not usual in the epithelioid subtype of malignant peripheral nerve sheath tumor. However, a variety of complicated and similar histological features can present in all these tumors and the microscopic features could not be the only basis for differentiation for these tumors.
In the current case, immunohistochemical examination shows that the tumor cells were diffusely positive for endothelia cell markers Factor VIII and Fli-1 and focally positive for CD31. However these markers are not absolutely specific for endothelial cells. The other mesenchymal tumors mentioned above should be ruled out. INI-1 expression has been found to be lost in some tumors including epithelioid sarcoma . In this case INI-1 expression was retained. The myoid tumor markers such as actin-sm and desmin were negative in this case. S-100, a marker usually positive in tumors arising from nervous system including malignant peripheral nerve sheath tumor, was also negative in this case. However even in malignant peripheral nerve sheath tumor, S-100 expression is not always detected . We need to differentiate theses tumors more carefully based on more information but not only on one marker like S-100. vimentin was diffusely positive in the tumor cells, which supports but cannot fully prove the tumor as a mesenchymal neoplasm. As for keratins, AE1/AE3 was focally but not diffusely positive in this case. AE1/AE3 was usually positive in cases of pseudomyogenic hemangioendothelioma reported so far [1–5, 10–14]. Some documents mentioned that the immunostaining pattern is diffuse. However the documents are limited and more cases are still in need to be studied to verify the immunostaining pattern of this marker. CD34 expression is usually negative in pseudomyogenic hemangioendothelioma, however a report indicates that it was positive in some cases . In a word, the immunophenotype of this tumor is still to be studied and characterized. From these information it may be more reasonable to considere this case as an endothelial neoplasm but not myoid tumor, peripheral nerve sheath tumor, or epithelioid sarcoma. Ki67 index in this case was about 5 % and not very high. MDM2 and CDK4 overexpression are not usually seen in benign tumors but quite common in intermediate or malignant mesenchymal tumors [15, 16] and was diffusely positive in this case. These three markers are helpful to understand the nature of the tumor and support the consideration of it as a tumor with a certain extent of malignant potentials.
However, the histological feature and immuostaining findings are not enough for fully understanding and characterizing the tumor of this case as usual. The clinical feature is important for the diagnosis and should be carefully studied as always. The patient of this case had experienced a long course of disease with the tumor about 10 years which indicates the tumor is relative indolent. Approximately 60 % of patients with pseudomyogenic hemangioendothelioma experience local recurrence of the tumor . In this case the patient experienced twice local recurrences at the same location after local excisions. After 10 years the tumor has developed a regional subcutaneous lymph node metastasis in her thigh. No distant metastasis in other organs was found in this patient. Pseudomyogenic hemangioendothelioma is now concluded as a intermediate, rarely metastasizing endothelial neoplasm. The clinical feature of this patient is also in accordance with that of pseudomyogenic hemangioendothelioma. Cancer can be caused by various factors including inflammation which can promote the formation of premalignant lesions and promote cancer progression. The immune system plays complicated roles in the progression of malignant tumors . In this case, the patient experienced a couple times of recurrence and at last developed lymph node metastasis. However, there wasn’t any clue of inflammation or auto-immune diseases related found in this patient. So far, the pathogenesis and mechanism involved in the progression of this tumor is not uncovered.
Pseudomyogenic hemangioendothelioma is a rare endothelial neoplasm which often mimics myoid and epithelioid tumors morphologically. A variety of mesenchymal neoplasms with similar architecture and cell morphology should be carefully differentiated from this tumor. For the diagnosis the immunostaining is very important but not decisive and enough. Clinical information including age, gender, tumor location, disease course and recurrence is important for appropriate diagnosis and fully understanding of the tumor and is indispensable. Analysis based on any single factor or incomplete information may easily lead to arbitrary conclusion. However the reports of this tumor are limited. Further studies on more cases are in need for fully understanding and appropriate diagnosis of it.
Written informed consent was obtained from the patient for publication of this case report and accompanying images.
This work was supported by the National Natural Science Foundation of China (no.81472599 to Chuifeng Fan, MD).
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am J Surg Pathol. 2003;27(1):48–57.View ArticlePubMedGoogle Scholar
- Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol. 2011;35(2):190–201.View ArticlePubMedGoogle Scholar
- Cai JN, Peng F, Li LX, Cheng YF, Wang J. Epithelioid sarcoma-like hemangioendothelioma: a clinicopathologic and immunohistochemical study of 3 cases. Zhonghua Bing Li Xue Za Zhi. 2011;40(1):27–31.PubMedGoogle Scholar
- Billings SD, Folpe AL, Weiss SW. Epithelioid Sarcoma-like hemangioendothelioma (pseudomyogenic hemangioendothelioma). Am J Surg Pathol. 2011;35(7):1088.View ArticlePubMedGoogle Scholar
- Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World health organization classifiction of tumors of soft tissue and bone. Pathology and genetics of tumors of soft tissue and bone. Lyon: IARC Press; 2013.Google Scholar
- Sheng W, Pan Y, Wang J. Pseudomyogenic hemangioendothelioma: report of an additional case with aggressive clinical course. Am J Dermatopathol. 2013;35(5):597–600.View ArticlePubMedGoogle Scholar
- Tokyol C, Uzüm N, Kuru I, Uluoglu O. Epithelioid sarcoma-like hemangioendothelioma: a case report. Tumori. 2005;91(5):436–9.PubMedGoogle Scholar
- Li HX, Fan QH, Zhang ZH, Zhang WM, Fan XS, Song GX. Clinicopathologic analysis of epithelioid sarcoma-like hemangioendothelioma. Zhonghua Bing Li Xue Za Zhi. 2012;41(11):767–8.PubMedGoogle Scholar
- Stuart LN, Gardner JM, Lauer SR, Monson DK, Parker DC, Edgar MA. Epithelioid sarcoma-like (pseudomyogenic) hemangioendothelioma, clinically mimicking dermatofibroma, diagnosed by skin biopsy in a 30-year-old man. J Cutan Pathol. 2013;40(10):909–13.PubMedGoogle Scholar
- Karakasli A, Karaaslan A, Erduran M, Capkin S, Tuna EB, Havitcioglu H. Pseudomyogenic (Epithelioid sarcoma-like) hemangioendothelioma with bone invasion. J Orthop. 2014;11(4):197–9.View ArticlePubMedGoogle Scholar
- Requena L, Santonja C, Martinez-Amo JL, Saus C, Kutzner H. Cutaneous epithelioid sarcomalike (pseudomyogenic) hemangioendothelioma: a little-known low-grade cutaneous vascular neoplasm. JAMA Dermatol. 2013;149(4):459–65.View ArticlePubMedGoogle Scholar
- Amary MF, O'Donnell P, Berisha F, Tirabosco R, Briggs T, Pollock R, et al. Pseudomyogenic (epithelioid sarcoma-like) hemangioendothelioma: characterization of five cases. Skeletal Radiol. 2013;42(7):947–57.View ArticlePubMedGoogle Scholar
- McGinity M, Bartanusz V, Dengler B, Birnbaum L, Henry J. Pseudomyogenic hemangioendothelioma (epithelioid sarcoma-like hemangioendothelioma, fibroma-like variant of epithelioid sarcoma) of the thoracic spine. Eur Spine J. 2013;22 Suppl 3:S506–11.View ArticlePubMedGoogle Scholar
- Ide YH, Tsukamoto Y, Ito T, Watanabe T, Nakagawa N, Haneda T, et al. Penile pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma with a novel pattern of SERPINE1-FOSB fusion detected by RT-PCR - Report of a case. Pathol Res Pract. 2015;211:456–20.View ArticleGoogle Scholar
- von Baer A, Ehrhardt A, Baumhoer D, Mayer-Steinacker R, Schultheiss M, Abdul-Nou T, et al. Immunohistochemical and FISH analysis of MDM2 and CDK4 in a dedifferentiated extraskeletal osteosarcoma arising in the vastus lateralis muscle: differential diagnosis and diagnostic algorithm. Pathol Res Pract. 2014;210(10):698–703.View ArticleGoogle Scholar
- Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23(9):1279–88.View ArticlePubMedGoogle Scholar
- Kristin SI, Amanda AF, Nicole RM. Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol. 2014;20(32):11160–81.View ArticleGoogle Scholar